Healthcare Industry News: Imprime PGG
News Release - March 10, 2011
Biothera Acquires MUC1 Anti-Cancer Monoclonal Antibody From AntisomaEAGAN, Minn.--(Healthcare Sales & Marketing Network)-- Biothera announced today that it has acquired the anti-cancer monoclonal antibody AS1402 from Antisoma for undisclosed terms.
AS1402 is a monoclonal antibody that targets an aberrant form of the cell-surface protein MUC1 that is widely expressed in many types of cancer. Prior to the acquisition, the experimental drug had been in Phase 2 development.
Biothera’s Imprime PGG® is a novel immunotherapy that works synergistically with anti-tumor monoclonal antibodies. Imprime PGG activates the largest population of the body’s immune cells (neutrophils), enabling them to recognize and kill antibody-targeted cancer cells.
Biothera plans to study the combination therapy of Imprime PGG and AS1402 in future cancer trials. The indication(s) has (have) yet to be determined.
“We believe the combination of Imprime PGG and AS1402 could create a potent therapy to treat a wide range of cancers,” said Dan Conners, President, Biothera Pharmaceutical Group.
“This deal gives Biothera the opportunity to pursue an interesting new approach with AS1402 while at the same time realising value for Antisoma,” said Nicholas Adams, Vice President of Business Development at Antisoma.
About Biothera, the Immune Health Company
Biothera is a privately held biotechnology company dedicated to improving immune health. The company is developing pharmaceuticals that engage the innate immune system to fight cancer. Its lead cancer drug Imprime PGG is currently in multiple Phase 2 clinical trials for non-small cell lung and in a Phase 3 for colorectal cancer. (www.biothera.com)
Antisoma is a London Stock Exchange-listed biopharmaceutical company that develops novel products for the treatment of cancer. The Company has operations in the UK and the US. Please visit www.antisoma.com for further information about Antisoma.
Source: Biothera Inc
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.